The SARAH Study

SARAH (SorAfenib versus Radioembolisation in Advanced Hepatocellular carcinoma) is a European multi-centre prospective randomised open-label study comparing the efficacy and safety of SIR-Spheres® Y-90 resin microspheres with sorafenib.

Patients with advanced HCC (Barcelona Clinic Liver Cancer [BCLC] stage C) with or without portal vein thrombosis and no extrahepatic spread, or patients with early/intermediate HCC (BCLC stage A or B) whose disease has progressed or recurred after previous therapies; and who are ineligible for surgical resection, ablation or liver transplantation were recruited.

The primary endpoint of the SARAH study is Overall Survival. Secondary endpoints include Safety, Progression-Free Survival at 6 months, Quality of Life, and Healthcare Costs.

The study completed enrolment of >460 patients in March 2015 and results are expected by mid-2017.

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.



This content is intended for healthcare professionals only

By clicking "Yes" you are confirming that you are a healthcare professional. If you are not a healthcare professional, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage